Biotech

All Articles

FibroGen gives up 75% people workers as property fails 2 even more tests

.FibroGen is significantly restructuring its business, giving up 75% of its own U.S. staff and stopp...

Tracon winds down full weeks after injectable PD-L1 inhibitor fall short

.Tracon Pharmaceuticals has determined to wane procedures weeks after an injectable immune system ga...

Ideaya bags alternative on Biocytogen bispecific ADC in $400M deal

.Ideaya Biosciences is wagering $400 million in biobucks that a bispecific antibody-drug conjugate (...

Takeda takes $140M loss on fallen short epilepsy medicine, proclaims FDA run

.We actually recognize that Takeda is hoping to locate a path to the FDA for epilepsy medicine sotic...

VBI Vaccinations apply for insolvency, finds possession sale

.Immunology biotech VBI Vaccinations is drifting alarmingly close to the defining moment, with strat...

Celldex anti-cKIT antitoxin decrease colonies in an additional stage 2 study

.It is actually challenging to muscular tissue in on a room as competitive as immunology, however Ce...

Boehringer offers up to $1.3 B for gate prevention biotech

.Boehringer Ingelheim is providing to $1.3 billion for Nerio Rehabs and a preclinical immune system ...

Ventyx's last hope for inflamed med sides in Crohn's failing

.Ventyx Biosciences' Crohn's health condition medicine did certainly not aid people achieve remissio...

Cognition's phase 2 beam records blemish Alzheimer's prospect

.Knowledge Therapeutics' stage 2 sparkle trial has taken some of the gloss off the Alzheimer's illne...

BMS axes bispecific months after submitting to run period 3 test

.Bristol Myers Squibb has actually had a whiplash change of mind on its BCMA bispecific T-cell engag...